Table: q1_q4_2020_prescription_drugs_intro_to_market , manufacturer_name like J*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Janssen Biotech, Inc.	57894050301	DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) Strength:1800mg / 15 mL Form:1 Single Vial	2020-05-04	7574.0000	While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals diagnosed with multiple myeloma. The pricing plan has WAC set for 1800mg / 15 mL subcutaneous injections at $7,574.00. The list price of DARZALEX FASPRO™ is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. DARZALEX FASPRO™ will also be discounted as required under the 340B program, Federal Supply Schedule, and other government programs. On June 3, 2020, approval was received in the EU.	None	None	None	None	None	None	None	None	The estimated number of patients in the United States with a condition for which DARZALEX FASPRO™ may be prescribed is not in the public domain or publicly available. DARZALEX FASPRO™ was developed by Janssen Biotech, Inc.	None
Jazz Pharmaceuticals, Inc.	68727071201	Zepzelca (lurbinectedin) 4mg lyophilized powder single dose vial	2020-07-07	6633.0000	None	1	8500	None	1	2019-12-19	200000000.0000	None	Lurbinectedin was licensed on December 19, 2019 through an exclusive license agreement between PharmaMar and Jazz Pharmaceuticals. Under the terms of the agreement, PharmaMar receives an upfront payment of $200 million with potential regulatory milestone payments of up to $250 million upon the achievement of accelerated and/or full regulatory approval of lurbinectedin by FDA within certain timelines. PharmaMar is also eligible to receive additional commercial milestone payments tied to future net sales of lurbinectedin.	None	None
Jazz Pharmaceuticals, Inc.	68727015001	Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution	2020-11-02	5110.1200	None	1	None	None	1	None	None	None	None	None	None